Human beta defensins may be a multifactorial modulator in the management of diabetic wound.

Abstract

Diabetic wound (DW) is considered as one of the serious complications associated with diabetes mellitus. Though some pharmacological approaches are available for managing DW, none of them has been reported to be very effective. Widely accepted options for its management include treatment of infection caused by various pathogens, wound debridement, reducing the period of the prolonged inflammatory phase, and supervision of the remodeling phase of wound healing. Satisfactory management of DW thus requires exploring new avenues for finding a potential therapeutic strategy. Literature shows that human beta defensins (HBDs) help in combating the insulin resistance by inhibiting the production of glucocorticoids, reducing chronic inflammation by acting through Toll-like receptor signaling pathway, and provoking cell migration, proliferation, angiogenesis, and stabilization of fibroblasts and keratinocytes, ultimately resulting in wound closure. In the present review, beneficial role of HBDs in the treatment of DW is discussed in detail.

• Authors: Bharat K R Sanapalli, Vidyasrilekha Yele, Rama S R Kalidhindi, Sachin K Singh, Monica Gulati, Veera V S R Karri
• Journal: Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society (Wound Repair Regen) Vol. 28 Issue 3 Pg. 416-421 (05 2020) ISSN: 1524-475X [Electronic] United States
• PMID: 31777130 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2019 by the Wound Healing Society.

Chemical References

• Anti-Infective Agents
• beta-Defensins

Topics

• Anti-Infective Agents (therapeutic use)
• Diabetes Complications (complications, therapy)
• Humans
• Skin Ulcer (etiology, pathology, therapy)
• beta-Defensins (therapeutic use)